NewAmsterdam Pharma prices $175.3M public offering of shares and pre-funded warrants

NewAmsterdam Pharma Co N.V.

Priced 4,488,159 ordinary shares at $19.00/share and 4,736,841 pre-funded warrants at $18.9999 each.
Gross proceeds of approximately $175.3 million before underwriting discounts and expenses.
Underwriters granted 30-day option for up to 1,383,750 additional shares, exercised in full.
Net proceeds expected to be approximately $188.8 million including option exercise.
Offering closed on February 16, 2024; Jefferies, Leerink, Piper Sandler, RBC Capital Markets as joint book-runners.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

NewAmsterdam Pharma Co N.V. entered into Underwriting Agreement with Jefferies LLC, Leerink Partners LLC, Piper Sandler & Co. and RBC Capital Markets, LLC, as representatives of the several underwriters valued at $188.8 million (effective 2024-02-13).

Action: entry
Agreement: underwriting
Counterparty: Jefferies LLC, Leerink Partners LLC, Piper Sandler & Co. and RBC Capital Markets, LLC, as representatives of the several underwriters
Value: $188.8 million
Effective: 2024-02-13

Exact text from the filing

On February 13, 2024, NewAmsterdam Pharma Company N.V. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC, Leerink Partners LLC, Piper Sandler & Co. and RBC Capital Markets, LLC, as representatives of the several underwriters listed on Schedule A thereto (the “Underwriters”), related to an underwritten public offering (the “Offering”) of 4,488,159 of the Company’s ordinary shares, nominal value €0.12 per share (the “Ordinary Shares”), at a public offering price of $19.00 per share

View on SEC.gov

1 material agreements filed in the last 30 days. Browse all material agreements →

NewAmsterdam Pharma Co N.V. filing history →

Source: SEC EDGAR

accession 0001193125-24-037559

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.